

Edison Investment Research **Initiates Coverage**

Melbourne, Australia, 30 April 2015

Edison Investment Research Limited has initiated coverage of clinical stage oncology company Prescient Therapeutics Limited (ASX: PTX).

The full report can be found under the Media/Press & Research Reports tab on the Company's website at: www.prescienttherapeutics.com.

Ends.

About Prescient Therapeutics

Prescient Therapeutics is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

Lead drug candidate PTX-200 inhibits an important tumor survival pathway known as AKT, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukaemia. This highly promising compound is now the focus of two current clinical trials. The first is a Phase 1b/2 study of PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York. The second is also a Phase 1b/2 trial in patients with recurrent or persistent platinum resistant ovarian cancer at Florida's Lee Moffitt Cancer Center. In addition, Prescient is planning a Phase 1b/2 trial evaluating PTX-200 as a new therapy for acute myeloid leukemia in 2015.

Prescient's second novel drug candidate, PTX-100, is a first in class compound with the ability to block important cancer-causing proteins such as Ral and Rho, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase 1 trial in advanced solid tumors. Prescient expects to commence Phase 1b/2 clinical trials in breast cancer and multiple myeloma in 2015. At the same time, Prescient plans to develop its novel p27 cancer biomarker as a companion diagnostic that will potentially identify those patients that are most likely to respond to PTX-100 therapy.

Further Inquiries:

Dr Robert Crombie
Managing Director
+61 439 361 331

Paul Hopper (Los Angeles)
Executive Director
+1 858-334-5820

Rudi Michaelson
Monsoon Communications
+61 3 9620 3333

Stephanie Carrington (New York)
Integrated Corporate Relations (ICR)
+1 646-277-1282